 NEW YORK--BUSINESS WIRE--- RCKT ASH2020--Rocket Pharmaceuticals, Inc. NASDAQ: RCKT Rocket, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today presents updated interim data from its Fanconi Anemia FA and Leukocyte Adhesion Deficiency-I LAD-I programs at the 62nd American Society of Hematology ASH Annual Meeting. The data are highlighted in two oral presentations. We are highly pleased with the data presented at ASH de 